CAS 1110813-31-4

dacomitinib

Description:

Dacomitinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It functions by irreversibly binding to the epidermal growth factor receptor (EGFR) and inhibiting its activity, which is crucial for tumor growth and proliferation. Dacomitinib is characterized by its high oral bioavailability and a relatively long half-life, allowing for once-daily dosing. The compound is typically administered in tablet form and is known for its potential side effects, which may include skin rash, diarrhea, and elevated liver enzymes. Its chemical structure features a quinazoline core, which is common among EGFR inhibitors, and it is classified as a targeted therapy due to its specificity for cancer cells harboring EGFR mutations. Dacomitinib's efficacy and safety profile have been evaluated in clinical trials, leading to its approval for use in certain patient populations, making it a significant option in the landscape of targeted cancer therapies.

Formula: C₂₄H₂₅ClFN₅O₂

InChI: InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

InChI key: InChIKey=LVXJQMNHJWSHET-AATRIKPKSA-N

SMILES: N(C=1C2=C(C=C(OC)C(NC(/C=C/CN3CCCCC3)=O)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4

Synonyms:

• (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxy-6-Quinazolinyl)-4-(1-Piperidinyl)-2-Butenamide
• (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
• 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
• Pf 00299804
• Pf 299804
• Pf-00299804-03
• Pf-299
• Pf299804
• Dacomitinib
• DacoMitinib,PF299804
• (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquizolin-6-yl)-4-(piperidin-1-yl)but-2-eMide
• dacomitinib (pan-HER inhibitor)
• DacoMitinib (PF299804, PF299)
• PF299
• Dacomitinib, >=98%
• DacoMitinib (PF-00299804)
• DacoMitinib (PF299804,PF-00299804)
• (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299)

Dacomitinib

CAS: 1110813-31-4

Dacomitinib

Purity: 99%

Molecular weight: 469.94g/mol

Ref: 54-PC109044

Dacomitinib

CAS: 1110813-31-4

Dacomitinib

Purity: ≥98%

Molecular weight: 469.94g/mol

Ref: 54-BUP15196

Dacomitinib

CAS: 1110813-31-4

Formula: C₂₄H₂₅ClFN₅O₂

Molecular weight: 469.95

Ref: 4Z-D-212001

Dacomitinib

CAS: 1110813-31-4

Formula: C₂₄H₂₇ClFN₅O₃

Molecular weight: 487.95

Ref: 7W-GP3436

Dacomitinib-d10

CAS: 1110813-31-4

Formula: C₂₄H₁₅D₁₀ClFN₅O₂

Color and Shape: Pale Yellow Solid

Molecular weight: 480.01

Ref: 4Z-D-212003

Dacomitinib

CAS: 1110813-31-4

Dacomitinib (PF299) is an oral selective inhibitor of EGFR, ERBB2, ERBB4 with IC50s: 6, 45.7, 73.7 nM.

Formula: C₂₄H₂₅ClFN₅O₂

Purity: 99.4% - 99.72%

Color and Shape: Solid

Molecular weight: 469.94

Ref: TM-T2483

Dacomitinib-13C-d3

CAS: 1110813-31-4

Formula: C₂₃₁₃CH₂₂D₃ClFN₅O₂

Molecular weight: 473.96

Ref: 4Z-D-212002

Dacomitinib

CAS: 1110813-31-4

Pan-EGFR inhibitor (HER1, HER2 and HER4); antineoplastic

Formula: C₂₄H₂₅ClFN₅O₂

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 469.95 g/mol

Ref: 3D-FD64992

Dacomitinib

Controlled Product

CAS: 1110813-31-4

Applications Dacomitinib is an Erb-inhibitor, or an inhibitor of the members of the epidermal growth factor receptor family. Used as an ant-cancer agent due to observation of over-expressed epidermal growth factor receptor in nearly all cases of squamous cell carcinoma in the head and neck.
References Williams, J. et al.: PLoS., 9, e98557 (2014); Peters, S. et al.: Canc. Treatment Rev., 40, 917 (2014);

Formula: C₂₄H₂₅ClFN₅O₂

Color and Shape: Neat

Molecular weight: 469.94

Ref: TR-D101575